Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Management of Posterior Reversible Encephalopathy Syndrome Induced by Carfilzomib in a Patient With Multiple Myeloma.

× No keyword cloud information.

8 in total

1. Smoldering Multiple Myeloma Associated Leukoencephalopathy Presenting with Holmes Tremor, Ataxia, and Pyramidal Syndrome.

Authors: Camila Catherine Aquino; Barbara Connolly; Anthony E Lang
Journal: Mov Disord Clin Pract Date: 2018-07-19

2. Synergistic anti-myeloma activity of the proteasome inhibitor marizomib and the IMiD immunomodulatory drug pomalidomide.

Authors: Deepika S Das; Arghya Ray; Yan Song; Paul Richardson; Mohit Trikha; Dharminder Chauhan; Kenneth C Anderson
Journal: Br J Haematol Date: 2015-10-12 Impact factor: 6.998

3. Targeting proteasome ubiquitin receptor Rpn13 in multiple myeloma.

Authors: Y Song; A Ray; S Li; D S Das; Y T Tai; R D Carrasco; D Chauhan; K C Anderson
Journal: Leukemia Date: 2016-04-27 Impact factor: 11.528

4. Phase 1 study of marizomib in relapsed or relapsed and refractory multiple myeloma: NPI-0052-101 Part 1.

Authors: Paul G Richardson; Todd M Zimmerman; Craig C Hofmeister; Moshe Talpaz; Asher A Chanan-Khan; Jonathan L Kaufman; Jacob P Laubach; Dharminder Chauhan; Andrzej J Jakubowiak; Steven Reich; Mohit Trikha; Kenneth C Anderson
Journal: Blood Date: 2016-03-23 Impact factor: 22.113

5. Marizomib irreversibly inhibits proteasome to overcome compensatory hyperactivation in multiple myeloma and solid tumour patients.

Authors: Nancy Levin; Andrew Spencer; Simon J Harrison; Dharminder Chauhan; Francis J Burrows; Kenneth C Anderson; Steven D Reich; Paul G Richardson; Mohit Trikha
Journal: Br J Haematol Date: 2016-05-09 Impact factor: 6.998

Management of Posterior Reversible Encephalopathy Syndrome Induced by Carfilzomib in a Patient With Multiple Myeloma.

1. Smoldering Multiple Myeloma Associated Leukoencephalopathy Presenting with Holmes Tremor, Ataxia, and Pyramidal Syndrome.

2. Synergistic anti-myeloma activity of the proteasome inhibitor marizomib and the IMiD immunomodulatory drug pomalidomide.

3. Targeting proteasome ubiquitin receptor Rpn13 in multiple myeloma.

4. Phase 1 study of marizomib in relapsed or relapsed and refractory multiple myeloma: NPI-0052-101 Part 1.

5. Marizomib irreversibly inhibits proteasome to overcome compensatory hyperactivation in multiple myeloma and solid tumour patients.

6. Verapamil as treatment for refractory status epilepticus secondary to PRES syndrome on a SARS-Cov-2 infected patient.

7. High Effectiveness in Actions of Carfilzomib on Delayed-Rectifier K⁺ Current and on Spontaneous Action Potentials.

8. Leukoencephalopathy During Daratumumab-Based Therapy: A Case Series of Two Patients with Multiple Myeloma.